Skip to Content
Merck
All Photos(1)

Documents

BM0028

Sigma-Aldrich

BMS-536924

≥98% (HPLC)

Synonym(s):

4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, BMS 536924

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H26ClN5O3
CAS Number:
468740-43-4
Molecular Weight:
479.96
MDL number:
MFCD20278190
UNSPSC Code:
12352200

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

room temp

SMILES string

CC1=CC(N2CCOCC2)=CC3=C1NC(C4=C(NC[C@@H](O)C5=CC(Cl)=CC=C5)C=CNC4=O)=N3

Biochem/physiol Actions

BMS-536924 is a potent, orally active, ATP-competitive insulin-like growth gactor-1 receptor (IGF1R) inhibitor that shows anticancer activities in preclinical models.

Features and Benefits

BMS-536924 is available through a partnership with Bristol-Myers Squibb (BMS). To learn more and view other BMS compounds, visit sigma.com/BMS.

Legal Information

Sold for research purposes only under agreement from BMS.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Beate C Litzenburger et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(1), 226-237 (2009-01-02)
This study aimed to test the ability of a new insulin-like growth factor receptor (IGF-IR) tyrosine kinase inhibitor, BMS-536924, to reverse the ability of constitutively active IGF-IR (CD8-IGF-IR) to transform MCF10A cells, and to examine the effect of the inhibitor
Jenny C Potratz et al.
Cancer research, 70(21), 8770-8781 (2010-10-21)
The insulin-like growth factor-1 receptor (IGF1R) is emerging as a promising therapeutic target in human cancers. In the high-risk childhood sarcomas Ewing family tumor and rhabdomyosarcoma, IGF1R-blocking antibodies show impressive antitumor activity in some but not all patients, and acquired
Carly Jade Dool et al.
Endocrine-related cancer, 18(6), 699-709 (2011-09-29)
Epidemiologic and experimental evidence suggest that a subset of breast cancer is insulin responsive, but it is unclear whether safe and effective therapies that target the insulin receptor (IR), which is homologous to oncogenes of the tyrosine kinase class, can

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service